Aethlon Medical, Inc. (OTCBB: AEMD)

Trading Symbol: AEMD

Presenter:

James A. Joyce

Chairman and CEO

This presentation may contain predictions, estimates, and other forward looking statements that involve risks and uncertainties, including whether and when new products are successfully developed and introduced by the Company, market acceptance of current or new products, regulatory delays, manufacturing delays, and other risks which may be detailed in Aethlon Medical’s SEC filings.

HOMELAND DEFENSE CONFERENCEWASHINGTON, DC. MARCH 30, 2004


Aethlon Medical is pioneering the development of viral filtration devices that rapidly reduce the presence of viruses and toxins in the blood.

“...at the forefront of developing promising new treatments...“ (The Washington Times)


The HemopurifierTM

Hemodialysis

Affinity Chromatography

An Expansive Platform TechnologyConverging Established Principles


HemopurifierTM Advantages

Mimics Immune Response

Antibody Immobilization

Fusion/Entry Inhibitor

Multiple Disease Treatment

Established Infrastructure


HemopurifierTM Markets

Biological Weapons

HIV/AIDS

Hepatitis-C (HCV)


Published Human Blood Studies

55%+ removal of HIV in three hours.

85%+ removal of HIV in twelve hours.

90% removal of gp120 in one hour.

58% removal of HCV in two hours.


Biological Weapon Targets

CDC CATEGORY “A” AGENTS Smallpox Viruses

Anthrax Bacterium

Botulinum Toxin

Hemorrhagic Fevers

Ebola

Marburg

Septic Shock Mediators

Genetically Engineered


Bioterrorism Challenges

Vast Number of Targets

Genetic Engineering

Vaccine & Drug Limitations

Pathogens are Inexpensive & Accessible

Easy to Deliver


Hemopurifier Advantages

Adjunctive

Sole Solution

Rapid Development & Deployment

Addresses Military & Civilian Requirements


National Center for Biodefense

U.S. Military - Countermeasures Against Biological Weapons

Improves Access to Government Grants & Contracts

Increases Scientific Resources, Advocates Charles Bailey, MD.

Ken Alibek, MD.


The Aethlon Science Team


Richard Tullis, Ph.D.

Developer of Infectious Disease and Biowarfare Hemopurifiers. Inventor and original patent holder of Antisense, and related DNA

synthesis technologies.

Co-founder and Director of Research of Molecular Biosystems (NYSE).

Founder of Synthetic Genetics, Inc., and Syngen Research, Inc.

Aethlon Chief Scientific Officer, Director


Kenneth Michael, Ph.D.

Founder, Past President & Chairman of The Regulatory Affairs Professionals Society (RAPS), an 8000 member International

Regulatory Affairs Organization. Director of Regulatory Affairs at Siemens Medical Systems.

Regulatory and Clinical Affairs Advisor


Nathan W. Levin, MD

Medical and Research Director of the Renal Research Institute, LLC.

Professor of Clinical Medicine at the Albert Einstein College of Medicine.

SCIENCE ADVISORY BOARD / Dialysis


Claudio Ronco, MD

Director of the Dialysis and Renal Transplantation at St. Bartolo Hospital in Vicenza, Italy.

Instrumental in the introduction of continuous hemofiltration and high flux dialysis in Europe.

Seventeen books on nephrology and dialysis.

350+ scientific papers.

Editorial board of twelve scientific journals.

Director of three international scientific societies.



Larry Cowgill, D.V.M., Ph.D.

Professor in the Department of Medicine and Epidemiology at the School of Veterinary Medicine, University of California.

Head of companion animal dialysis at the Veterinary Medical Teaching Hospital at UC Davis and the UC Veterinary Medical Center-San Diego.

Leading authority in managing animal dialysis clinical programs.



Raveendran Pottathil, Ph.D.

Former Section Director of Retroviral Research at Hoffman La Roche.

Advisor to World Health Organization’s Sexually Transmitted Diseases and Global Vaccination Program.

Co-founder of Specialty Biosystems, Inc. President of AccuDx, Inc.

SCIENCE ADVISORY BOARD / Infectious Disease


Jean-Claude Chermann, Ph.D.

AIDS virus discoverer.

Director of Research of the Pasteur Institute. Director of Research of INSERM (French National Institute of

Health and Medical Research).

First to demonstrate that HIV is a retrovirus.

First use of HIV anti-retroviral agent in humans.

First to demonstrate HIV infection in US patients through the detection of antibodies.



Pedro Cuatrecasas, MD

Inventor of Affinity Chromatography.

Former President of Pharmaceutical Research at Parke-Davis.

Corporate Vice President for Warner Lambert Company.

Senior Vice President and Director of Glaxo Inc.

Vice President, R&D, and Director, of Burroughs Wellcome.

Involved in the commercialization of over forty novel medicines.

Member of the National Academy of Sciences, The Institute of Medicine, American Academy of Arts & Sciences.

Numerous awards, including The Wolf Prize in Medicine.

400+ scientific publications.



Targeted 12-Month Value Drivers

Introduction of Aethlon to the Financial Industry

Partnerships

Biowarfare Animal Data

Human Trial Initiation

Grant Income


Investment Data

OTCBB: “AEMD”

Stock Price (3/26/04): $1.85

Market Capitalization (3/26/04) : $16.9 million

Shares Outstanding (2/12/04): 9,122,711


Conclusion

NOT IF, BUT WHEN

Documents

Aethlon Medical, Inc. (OTCBB: AEMD)